Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520763 | 0.82 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL14520037 | 0.82 | KMT2A (0.57) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL14520042 | 0.81 | MAOB (0.44) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL14519923 | 0.81 | ALDH1A1 (0.55) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL14866325 | 0.81 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL14519921 | 0.81 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2KMT2AGAAMAPK1 | |
| SCHEMBL5960683 | 0.79 | SMN1; SMN2 (0.67) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL10959144 | 0.79 | ALDH1A1 (0.54) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL14114761 | 0.79 | L3MBTL1 (0.57) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL13049842 | 0.78 | L3MBTL1 (0.69) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | L3MBTL1 2366/4885ALDH1A1 1079/4885SMN1; SMN2 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.